US Biotechnology Market 2024–2033

Reports Description

The US biotechnology market was valued at USD 583.8 billion in 2024 and is expected to reach USD 1797.8 billion by 2033, with a CAGR of 12.3% during the forecast period 2024 – 2033.

Biotechnology is a multidisciplinary field that merges biology with technology to develop innovative products and solutions for various industries. It involves the manipulation of living organisms or their components to create useful products, processes, or technologies.

US Biotechnology Market: Growth Factors

Growing innovation in DNA sequencing

Innovation in DNA sequencing has been a transformative force propelling the US biotechnology market forward, revolutionizing research, medicine, and agriculture. The advent of high-throughput sequencing technologies, such as next-generation sequencing (NGS), has dramatically accelerated the pace and reduced the cost of DNA sequencing, unlocking unprecedented insights into the genetic makeup of organisms.

This has fuelled advancements across various sectors, including personalized medicine, where the ability to sequence an individual’s genome rapidly and affordably has paved the way for tailored diagnostics, treatments, and drug development.

Furthermore, in agriculture, DNA sequencing has enabled the development of genetically modified organisms (GMOs) with improved traits such as pest resistance and higher yields, contributing to more sustainable and productive farming practices.

Additionally, the application of DNA sequencing in environmental and microbial studies has deepened our understanding of ecosystems, biodiversity, and microbial communities, offering solutions to environmental challenges and facilitating the discovery of novel biotechnological products.

As a result, the continuous innovation in DNA sequencing technologies has not only driven the growth of the US biotechnology market. Still, it has also catalysed advancements with far-reaching impacts on human health, agriculture, and the environment.

Increasing need for effective clinical interventions

The increasing need for effective clinical interventions is a significant driving force behind the growth of the US biotechnology market. As medical advancements push the boundaries of treatment options, there is a growing demand for innovative therapies to address complex diseases and medical conditions.

Biotechnology companies play a pivotal role in this landscape by developing cutting-edge pharmaceuticals, diagnostic tools, and therapeutic solutions that leverage the latest scientific discoveries. These interventions promise improved patient outcomes, enhanced quality of life, and even cures for previously untreatable conditions.

Moreover, as healthcare providers and policymakers prioritize personalized medicine and precision therapies, biotechnology firms are at the forefront of developing tailored treatments that target specific genetic profiles or disease mechanisms.

This emphasis on precision medicine improves treatment efficacy and reduces adverse effects and healthcare costs. Additionally, the COVID-19 pandemic has underscored the importance of biotechnology in rapidly developing vaccines, therapeutics, and diagnostics to combat emerging infectious diseases.

Consequently, the demand for biotechnological innovations continues to escalate, driving investment, research, and development activities within the US biotechnology sector, fuelling its growth and contributing to the overall advancement of healthcare.

US Biotechnology Market: Restraints

High cost

The high cost of innovation drives the US biotechnology market, shaping its dynamics in various ways. Research and development (R&D) expenses constitute a significant portion of biotech companies’ budgets, with the need for cutting-edge technologies, specialized equipment, and skilled personnel amplifying costs.

Additionally, stringent regulatory requirements imposed by agencies like the FDA necessitate extensive testing and validation processes, further inflating expenses. Moreover, the inherently risky nature of biotech R&D, characterized by high failure rates and prolonged development timelines, escalates financial risk for companies and investors alike.

Consequently, firms often price their products, such as novel therapeutics or diagnostics, at premium rates to recoup investments and sustain profitability. The complex interplay of these factors contributes to the perception of biotechnological innovations as high-cost ventures, shaping investment strategies, market dynamics, and access to healthcare solutions.

While the high cost barrier may pose challenges, it also underscores the critical role of innovation incentives, intellectual property protections, and strategic investments in driving progress within the US biotechnology sector.

US Biotechnology Market: Opportunities

Increased  R&D to develop genomic techniques

Increased research and development (R&D) efforts to develop genomic techniques have driven the growth of the US biotechnology market. Genomic techniques, such as next-generation sequencing (NGS), CRISPR-Cas9 gene editing, and gene expression profiling, have revolutionized the understanding of genetic mechanisms underlying diseases and biological processes.

By enabling researchers to analyse entire genomes rapidly and cost-effectively, these techniques have unlocked vast opportunities for biotechnological innovation. In the healthcare sector, genomic techniques have facilitated the development of personalized medicine, where treatments are tailored to individual genetic profiles, leading to more precise diagnoses and therapies.

This personalized approach improves patient outcomes and reduces healthcare costs by minimizing ineffective treatments and adverse drug reactions.

Moreover, genomic techniques have accelerated drug discovery and development by enabling the identification of novel drug targets and biomarkers, streamlining preclinical and clinical trials, and optimizing drug efficacy and safety profiles.

Beyond healthcare, genomic techniques have wide-ranging applications in agriculture, environmental conservation, and industrial biotechnology. Consequently, the increased R&D focus on genomic techniques has catalyzed the growth of the US biotechnology market, attracting investment, fostering innovation, and driving economic prosperity by creating new products, services, and job opportunities.

US Biotechnology Market: Segmentation Analysis

The US Biotechnology market is segmented by technology and application.  Based on technology, the market is classified into nanobiotechnology, tissue engineering and regeneration, DNA sequencing, cell-based assays, fermentation, PCR technology, chromatography, etc.

DNA Sequencing dominated the market in 2023 with a market share of 25.0% and is expected to keep its dominance during the forecast period 2024-2033.  DNA sequencing has been a transformative force driving the US biotechnology market due to its pivotal role in advancing various fields, from healthcare to agriculture.

DNA sequencing has facilitated breakthroughs in personalized medicine, genetic diagnostics, and drug development by enabling researchers to decode the genetic information of organisms with unprecedented speed and accuracy.

The ability to sequence an individual’s genome quickly and cost-effectively has revolutionized healthcare, allowing for tailored treatments based on a patient’s genetic makeup, thus improving outcomes and reducing healthcare costs.

Moreover, DNA sequencing has spurred innovation in agriculture, enabling the development of genetically modified organisms (GMOs) with enhanced traits such as disease resistance and higher yields, contributing to global food security.

Additionally, the widespread adoption of next-generation sequencing (NGS) technologies has fuelled growth in the biotechnology sector by lowering the barriers to entry for researchers and enabling large-scale genomic studies that uncover novel insights into human biology and disease mechanisms.

This technological advancement has attracted significant investment from both the public and private sectors, leading to the proliferation of biotechnology startups and the expansion of established companies, further driving the growth of the US biotechnology market.

Based on application, the market is classified into health, food & agriculture, natural resources & environment, industrial processing, bioinformatics and others. Health dominated the market in 2023 with a market share of 26.1% and is expected to keep its dominance during the forecast period 2024-2033.

The health sector drives the US biotechnology market through many interconnected mechanisms. The demand for advanced medical treatments and therapies, particularly in oncology, infectious diseases, and genetic disorders, fuels the need for innovative biotechnological solutions.

This demand is spurred by factors including an aging population, increasing prevalence of chronic diseases, and rising healthcare expenditure. Biotechnology companies respond to these needs by developing cutting-edge drugs, diagnostics, and medical devices that offer improved efficacy, safety, and precision compared to conventional treatments.

Furthermore, research collaborations and funding initiatives reinforce the symbiotic relationship between the health sector and biotechnology.

Academic institutions, government agencies, and private foundations contribute substantial resources towards basic and translational research, driving scientific discoveries and technological advancements. These collaborations facilitate the translation of research findings into clinical applications, fostering the development of novel biopharmaceuticals, gene therapies, and personalized medicine approaches.

Additionally, regulatory frameworks and reimbursement policies within the health sector significantly influence the commercialization and adoption of biotechnological innovations. Stringent regulatory oversight ensures biopharmaceutical products’ safety, quality, and efficacy, while reimbursement mechanisms incentivize healthcare providers to adopt cost-effective biotechnological solutions.

Overall, the health sector serves as both a catalyst and a beneficiary of the dynamic growth and innovation within the US biotechnology market, driving improvements in patient care, healthcare outcomes, and economic prosperity.

Report Scope

US Biotechnology Market: Recent Developments

• In October 2023, Amgen announced that it had completed its acquisition of Horizon Therapeutics plc. Horizon Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for rare genetic and autoimmune diseases.

• In December 2022, Merck KGaA announced a collaboration with Mersana Therapeutics to advance the development of antibody-drug conjugates (ADCs), specifically focusing on novel STING-agonist ADCs targeting up to two distinct targets. This collaboration aimed at harnessing the potential of ADCs for therapeutic innovation.

• In January 2023, Anima Biotech collaborated with AbbVie to accelerate the development of novel mRNA biology modulators to treat various oncology and immunology targets.

• In October 2023, Gilead Science’s subsidiary, Kite and Epicrispr Biotechnologies, announced a research collaboration and licensing agreement to utilize Epic Bio’s gene regulation platform in developing advanced cancer cell therapies.

• In September 2023, Biogen announced that the US Food and Drug Administration (FDA) had approved CONFIDENCE (tocilizumab-above) in its intravenous form, representing a biosimilar monoclonal antibody concerning ACTEMRA.

List of the prominent players in the US Biotechnology Market:

• AstraZeneca
• Gilead Sciences Inc.
• Bristol-Myers Squibb
• Sanofi
• Biogen
• Abbott Laboratories
• Pfizer Inc.
• Amgen Inc.
• Novo Nordisk A/S
• Merck KGaA
• Johnson & Johnson Services Inc.
• Novartis AG
• Hoffmann-La Roche Ltd.
• Lonza
• Others

These key players are adopting various growth strategies, such as mergers & acquisitions, joint ventures, expansion, strategic alliances, new product launches, etc. to enhance their business operations and revenues.

The US Biotechnology Market is segmented as follows:

By Technology

• Nanobiotechnology
• Tissue Engineering and Regeneration
• DNA Sequencing
• Cell-based Assays
• Fermentation
• PCR Technology
• Chromatography
• Others

By Application

• Health
• Food & Agriculture
• Natural Resources & Environment
• Industrial Processing
• Bioinformatics
• Others